Complete Guide to Breast Cancer Treatment in Germany
Breast cancer occurs when abnormal cells in the breast grow uncontrollably and may invade surrounding tissue or spread to other parts of the body. It is not a single disease. Treatment depends on the cancer stage, hormone receptor and HER2 status, tumor characteristics, recurrence risk, and the patient’s overall health.
In Germany, breast cancer treatment is provided through DKG-certified multidisciplinary breast centers, where specialists develop individualized treatment plans. The 2026 S3 guideline emphasizes treatment decisions based on tumor biology, disease stage, patient characteristics, and individual recurrence risk [1]. For patients exploring specialized care, TIG GmbH can provide information on treatment options and international patient services.
This guide covers diagnosis, staging, treatment, survival data, treatment costs, and what international patients can expect when seeking breast cancer care in Germany.
Breast cancer develops when abnormal cells in the breast grow uncontrollably and may invade surrounding tissue or spread to other parts of the body. Most breast cancers begin in the milk ducts or milk-producing lobules. The two most common invasive types are invasive ductal carcinoma and invasive lobular carcinoma. Ductal carcinoma in situ (DCIS) is a non-invasive form of breast cancer confined to the ducts and is generally considered stage 0 disease.
Breast cancer is the most common cancer among women in Germany. Risk increases with age, particularly after 50. Risk factors include increasing age, a family history of breast or ovarian cancer, inherited pathogenic variants such as BRCA1 or BRCA2, hormonal and reproductive factors, alcohol consumption, excess body weight after menopause, and physical inactivity. Most breast cancers, however, are not caused by an inherited BRCA1 or BRCA2 pathogenic variant [1] [3].
Common symptoms include:
1. New lump or thickening in the breast or armpit.
2. Change in breast size, shape, or contour.
3. Skin changes such as dimpling, redness, or thickening.
4. Nipple inversion or unusual nipple discharge, particularly bloody discharge.
5. Persistent breast or nipple changes that are new or unexplained.
Early breast cancer may cause no noticeable symptoms and can be detected through routine mammography. Germany’s national mammography screening program offers women aged 50–75 screening every two years. Women with breast symptoms or a previous breast cancer diagnosis are evaluated through diagnostic care rather than routine screening [1].
Once a lump or an abnormal screening result raises concern, diagnostic workup typically begins with a clinical breast exam, imaging, and tissue sampling.
1. Mammography and ultrasound: Mammography is a key imaging test, while ultrasound is used as an adjunct in selected patients, including when evaluating dense breast tissue or a specific breast abnormality.
2. Breast MRI: Used selectively, such as in patients at high genetic risk, when conventional imaging is inconclusive, or when additional imaging is needed for treatment planning; it is not routinely required for every patient.
3. Core needle biopsy: Confirms malignancy and allows pathological assessment of tumor type, grade, hormone receptors, HER2 status, and other biomarkers when clinically indicated.
4. Staging scans: CT, bone scintigraphy, PET-CT, or other systemic imaging may be used when the stage, symptoms, examination findings, or other clinical features raise concern for metastatic disease. Routine systemic staging is generally not recommended for asymptomatic patients with early-stage breast cancer [1] [5].
Once biopsy and imaging confirm the diagnosis, breast cancer is classified from stage 0 to IV based on tumor size, lymph node involvement, and whether the cancer has spread to distant organs. Treatment is further tailored to tumor biology, including hormone receptor and HER2 status. Treatment planning also considers recurrence risk, patient characteristics, and treatment preferences [1].
Treatment may include breast-conserving surgery or mastectomy with appropriate axillary staging. Depending on tumor biology, stage, recurrence risk, and patient factors, treatment may also include radiotherapy, endocrine therapy, chemotherapy, HER2-targeted therapy, immunotherapy, or other systemic treatments [1] [5].
For many locally advanced or high-risk tumors, treatment begins with neoadjuvant systemic therapy to reduce tumor burden and assess treatment response, followed by surgery and radiotherapy when indicated [1].
In selected patients with limited metastatic disease, local treatments such as surgery or radiotherapy may be considered alongside systemic therapy, depending on the sites of metastases, tumor biology, symptoms, and overall treatment goals [6].
Survival Rates and Prognosis in Certified German Centers
Survival statistics describe outcomes for large groups of similar patients; they cannot predict your individual outcome. Relative survival compares survival among people with cancer with the survival expected in the general population of the same age and sex.
Using U.S. SEER data, the American Cancer Society reports the following 5-year relative survival rates for women diagnosed between 2015 and 2021, grouped by extent of spread at diagnosis [8].
At diagnosis, breast cancer has a 5-year relative survival rate of >99% for localized disease, when the cancer is confined to the breast with no spread to lymph nodes or distant sites; 87% for regional disease, when it has spread to nearby lymph nodes or tissue; and 32% for distant disease (metastatic/stage IV), when it has spread to distant organs. Across all stages combined, the 5-year relative survival rate is 92%.
German registry data report an overall 5-year relative survival of roughly 87–88%, although estimates vary by reporting period and methodology [3] [4]. National and international figures are not directly comparable, since registries differ in staging distribution and methodology.
Overall prognosis is also determined by:
1. Biomarker Profile: Hormone receptor (ER/PR) and HER2 status.
2. Disease Burden: Tumor grade and lymph node involvement.
3. Treatment Response: A pathologic complete response after neoadjuvant therapy is generally associated with a more favorable prognosis, particularly in triple-negative and HER2-positive disease [1] [5].
Because prognosis depends heavily on tumor biology and stage, treatment in certified German breast centers combines surgery and radiation with systemic therapy chosen according to tumor biology, coordinated through a multidisciplinary tumor board.
1. Breast-conserving surgery (lumpectomy): Removes the tumor while preserving most of the breast. For eligible early-stage cancers, it offers comparable oncologic outcomes to mastectomy when combined with appropriate radiotherapy.
2. Mastectomy: Removes the entire breast and may be recommended for extensive or metacentric disease, when breast-conserving surgery would not provide an appropriate oncological or cosmetic result, in some genetically high-risk situations, or according to informed patient preference.
3. Lymph node surgery: Sentinel lymph node biopsy is commonly used for axillary staging in clinically node-negative patients. In selected patients with limited sentinel-node involvement, axillary lymph-node dissection may be omitted when the clinical setting, type of breast surgery, radiotherapy plan, tumor characteristics, and other guideline criteria support this approach.
4. Breast reconstruction: Reconstruction using implants or the patient’s own tissue may be performed immediately or delayed, depending on tumor characteristics and planned radiation [1] [2].
1. Chemotherapy: May be given before or after surgery when indicated. The regimen is selected according to tumor subtype, stage, recurrence risk, treatment response, comorbidities, and other patient-specific factors.
2. Endocrine therapy: Tamoxifen, aromatase inhibitors, and, when appropriate, ovarian function suppression are the main systemic treatments for hormone-receptor-positive breast cancer. Therapy is often prescribed for at least five years, with extended treatment considered for some patients based on recurrence risk, menopausal status, and tolerability [1].
3. HER2-targeted therapy: Treatment depends on disease stage, HER2 status, recurrence risk, and previous therapy. Trastuzumab, with or without pertuzumab, is used in appropriate HER2-positive early-stage disease; trastuzumab emtansine may be used when residual invasive disease remains after neoadjuvant therapy; and trastuzumab deruxtecan is an important option in selected HER2-positive, HER2-low, or HER2-ultralow metastatic settings according to current regulatory indications and prior treatment [9].
4. CDK4/6 inhibitors: Agents such as abemaciclib and ribociclib may be combined with endocrine therapy in selected patients with hormone-receptor-positive, HER2-negative early-stage or advanced/metastatic breast cancer, depending on disease risk, treatment setting, and regulatory indications [7].
5. PARP inhibitors: Olaparib is EU-approved as adjuvant treatment for germline BRCA-mutated, HER2-negative, high-risk early breast cancer [11].
6. Immunotherapy: Pembrolizumab has established indications in specific triple-negative breast cancer settings, including selected high-risk early-stage disease and PD-L1-positive unresectable or metastatic disease. It is not routinely used as systemic treatment for hormone-receptor-positive or HER2-positive breast cancer [10].
Radiotherapy is routinely recommended after breast-conserving surgery in most patients. After mastectomy, it may be recommended based on factors such as tumor size, lymph-node involvement, margin status, and other clinic pathological features [1]. Hypo fractionated radiotherapy, which delivers treatment in fewer sessions using a higher dose per fraction, is widely used in many breast cancer treatment settings. Radiation may also be used for symptom control in metastatic disease, such as painful bone lesions, where its intent is palliative.
Biomarker testing can identify patients who may be eligible for additional targeted treatments in advanced breast cancer. For example, PIK3CA alterations can be relevant when selecting targeted therapy for some patients with hormone-receptor-positive, HER2-negative advanced disease. Trastuzumab deruxtecan is also approved in the European Union for specific HER2-low or HER2-ultralow metastatic breast cancer settings, subject to the applicable treatment history and regulatory criteria [9]. For tumors that do not respond to standard options, clinical trials at German university cancer centers may offer access to investigational treatments, evaluated case by case rather than as a routine alternative to standard care.
Tumor subtype is a key factor in selecting systemic treatment alongside stage, tumor characteristics, and recurrence risk. German and international guidelines base systemic therapy recommendations primarily on hormone receptor and HER2 status.
Triple-negative breast cancer (TNBC), defined by the absence of estrogen receptor, progesterone receptor, and HER2 expression, accounts for approximately 15% of breast cancers and is more common in younger patients and in some patients with germline BRCA1 pathogenic variants. Chemotherapy remains a treatment backbone; for high-risk early-stage disease, pembrolizumab combined with chemotherapy is a guideline-supported option, and PARP inhibitors may be considered for patients with a germline BRCA mutation [1] [10] [11].
HER2-positive breast cancer is treated with HER2-directed therapy combined with chemotherapy in appropriate early-stage and advanced settings. Depending on stage, recurrence risk, treatment response, and previous therapy, options may include trastuzumab, pertuzumab, trastuzumab emtansine, and trastuzumab deruxtecan [1] [9].
Hormone-receptor-positive, HER2-negative breast cancer is the most common biological subtype, accounting for the majority of breast cancer cases. Endocrine therapy is a mainstay of treatment across disease stages, while CDK4/6 inhibitors may be added for selected patients with high-risk early-stage or advanced/metastatic disease. In selected hormone-receptor-positive, HER2-negative early cancers, validated genomic assays may help estimate recurrence risk and inform chemotherapy decisions, particularly when the benefit of chemotherapy is uncertain [1] [7].
Stage IV disease, whether present at diagnosis or arising later, is treated mainly with systemic therapy chosen by receptor and biomarker status. Because hormone-receptor and HER2 status can differ between the primary tumor and a metastasis, biopsy of an accessible metastatic lesion is generally recommended when clinically feasible and when the result could influence treatment selection [6]. The goal is to control disease, manage symptoms, and maintain quality of life.
1. Local treatment for selected patients: Surgery or radiotherapy may be considered for limited metastatic disease, painful or structurally threatening bone metastases, brain metastases, or other sites where local control is clinically appropriate. The role and intent of local treatment depend on disease extent, tumor biology, symptoms, and the overall treatment strategy.
2. Multidisciplinary support: Palliative care, pain management, and psycho-oncological support are typically integrated alongside ongoing cancer treatment [1].
The cost of breast cancer treatment in Germany varies substantially depending on the stage and subtype of cancer, diagnostic requirements, treatment approach, medication regimen, length of hospitalization, and whether reconstruction or additional procedures are required. For international patients, an individualized estimate is usually prepared after the hospital reviews the pathology report, imaging, previous treatment history, and proposed treatment plan.
1. Diagnostics: Mammography, ultrasound, MRI, biopsy, and biomarker or genomic testing.
2. Surgery: Cost depends on whether it is breast-conserving surgery or mastectomy, and whether reconstruction is included.
3. Systemic therapy: Chemotherapy, targeted therapy, and immunotherapy are usually the largest cost components, mainly due to medication prices.
4. Radiation: Cost depends on the number of sessions and the technique used.
Because costs vary by hospital and by case, TIG GmbH can arrange a personalized, itemized cost estimate once your medical records are available. For international patients, a treatment quotation may include diagnostic investigations, surgery and hospitalization, systemic therapy, radiotherapy, medication, pathology review, and follow-up services. The exact items included should be confirmed with the hospital before treatment begins.
International patients typically follow a similar sequence when arranging breast cancer treatment or a second opinion in Germany.
1. Submit Medical Records pathology reports, imaging, and prior treatment summaries are submitted for review by a German hospital or specialist.
2. Receive Treatment Recommendation and Cost Estimate the hospital provides a proposed plan and a cost estimate specific to your case; review time varies by hospital and case complexity.
3. Hospital Appointment and Medical Visa after the treatment plan and appointment are confirmed, international patients can apply for the appropriate German medical visa when required. Visa requirements differ by country of residence and should be verified with the responsible German mission before travel.
4. Travel and Treatment in Germany patients travel for consultations, procedures, and any inpatient care required. International patient services vary by hospital and may include medical-record coordination, interpretation, scheduling, and logistical support. Confirm these services before travel.
5. Follow-Up Care after active treatment, follow-up may continue with the German hospital, a physician at home, or both, depending on ongoing therapy such as endocrine treatment.
Overall duration depends heavily on the treatment plan: surgery alone may involve a hospital stay of a few days plus several weeks of recovery, while a combined course of neoadjuvant chemotherapy, surgery, and radiation can extend over several months, with endocrine therapy continuing for years afterward. An exact timeline is confirmed once a treatment plan is in place.
DKG-certified breast centers: meet defined standards for case volume, multidisciplinary staffing, and outcome reporting [2].
Biomarker-guided treatment: German breast centers use tumor characteristics such as hormone-receptor and HER2 status, and additional biomarkers when clinically indicated, to help determine appropriate systemic treatment.
Modern radiotherapy and systemic treatment: certified centers provide access to established radiotherapy approaches and guideline-supported targeted treatments, with specific technologies and therapies varying between hospitals.
Multidisciplinary tumor boards: surgeons, oncologists, radiologists, pathologists, and radiation oncologists review each case together.
International patient support: record review, treatment coordination, and interpreter support are available at many hospitals, although exact services vary by hospital and should always be confirmed directly.
1. How much does breast cancer treatment cost in Germany?
It depends on your stage and treatment plan surgery, radiation, chemotherapy, and targeted therapy each contribute differently to the total. An accurate estimate is only possible after a hospital reviews your pathology report and imaging.
2. What are the treatment options for breast cancer in Germany?
Depending on stage and subtype, options include breast-conserving surgery or mastectomy, sentinel lymph node biopsy or axillary dissection, radiation, chemotherapy, endocrine therapy, HER2-targeted therapy, CDK4/6 inhibitors, PARP inhibitors, immunotherapy, or a clinical trial [1] [5].
3. Which are the best breast cancer hospitals in Germany?
Germany has a nationwide network of DKG-certified breast centers meeting defined standards for multidisciplinary care. There is no single “best” hospital for every patient — the right center depends on your tumor characteristics and the treatments required.
4. How long does breast cancer treatment take?
Surgery alone may need a hospital stay of a few days plus several weeks of recovery. A combined course of neoadjuvant chemotherapy, surgery, and radiation can span several months, with endocrine therapy continuing for years afterward in hormone-receptor-positive disease.
5. What is the survival rate for breast cancer?
U.S. SEER data show 5-year relative survival above 99% for localized disease, 87% for regional spread, 32% for distant metastatic disease, and 92% across all stages combined [8]. Germany’s national registry reports an overall 5-year relative survival of about 87% [3]. These are population-level statistics and cannot predict an individual outcome.
6. Is treatment in Germany suitable for international patients?
Germany treats international patients, but the level of dedicated support varies between hospitals. You should confirm record-review procedures, language services, scheduling, payment requirements, and follow-up arrangements before travelling.
If you or a family member has been diagnosed with breast cancer, send your pathology report, imaging, and treatment history to TIG GmbH for review by a specialist team. A specialist review can help confirm your diagnosis, outline treatment options, and support informed decision-making before travelling for care.
References
3. Deutsche Krebsgesellschaft, ONKO-Internetportal. Brustkrebs: Erkrankungsverlauf.
8. American Cancer Society. Survival Rates for Breast Cancer (based on SEER data).
9. European Medicines Agency. Enhertu (trastuzumab deruxtecan): EPAR Medicine Overview.
10. European Medicines Agency. Keytruda (pembrolizumab): EPAR Medicine Overview.
11. European Medicines Agency. Lynparza (olaparib): EPAR.
Our benefits:
.webp)
 (1).webp)
.webp)
.jpg)
 (1).webp)
.jpg)
